Johnson & Johnson (NYSE:JNJ) is expecting its COVID-19 vaccine to reach $2.5 billion in sales this year, despite concerns about the injection’s efficacy against the dreaded Delta variant. [soros] Q2 2021 hedge fund letters, conferences and more Second Quarter Results On Wednesday, the company released its financial results for the second quarter, beating Wall Street […]
https://www.valuewalk.com/jj-covid-vaccine-sales-2-5-billion-2021/
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Johnson and Johnson Charts.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Johnson and Johnson Charts.